Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C
virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared
outcomes in treated and untreated patients with decompensated cirrhosis. Methods Patients
with HCV and decompensated cirrhosis or at risk of irreversible disease were treated in an
expanded access programme (EAP) in 2014. Treatment, by clinician choice, was with
sofosbuvir, ledipasvir or daclatasvir, with or without ribavirin. For functional outcome …